GeneDx Holdings Corp. - Class A Common Stock (WGS)

Documentation rules and Medicaid expansion are reshaping volume and margins.

GeneDx (NASDAQ:WGS) reported third-quarter revenue of $123.1 million and raised its full-year profitability outlook, even as new documentation requirements led the genetic testing company to lower its expectations for test volume growth. Management said the company is requiring more payer documenta

Genomic testing volume surged 32% as profitability returned ahead of schedule.

GeneDx (NASDAQ:WGS) reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability one quarter earlier than previously expected, while maintainin

GeneDx leverages AI-driven analytics for healthcare insights; a key insider recently trimmed their stake, according to SEC filings.

GeneDx Holdings, known for AI-driven health data, reported a notable insider buy amid continued momentum in precision medicine services.

Check out these three stocks that insiders are buying and selling, including giants in oil and AI, as well as a small gene stock seeing huge swings.

GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.

AI-driven health intelligence provider GeneDx attracted a notable insider buy, as recent filings highlight activity amid a volatile year.

One of these stocks plummeted 49% on Tuesday.

GeneDX's latest quarterly report arrived with a lot of bad news for investors.

GeneDx (WGS) Q1 2026 Earnings Transcript

GeneDx (WGS) Q1 2025 Earnings Call Transcript

GeneDx (WGS) Q2 2025 Earnings Transcript

Three stocks that have fallen more than 23% this year were on the Ark Invest CEO's shopping radar on Tuesday.

Ark Invest's CEO kicked off the new trading week with a little shopping.

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.